Risk factor
Very high price volatility
Profitability factor
Very poor margins and returns
About
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.
Target Price
The average target price of JBIO is 20 and suggests 34% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell